BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) investors concerning the Company and its officers’ possible violations of federal securities laws.
On September 26, 2018, TG Therapeutics announced that it could not proceed with the interim analysis of one of its leading product candidates, Ublituximab (TG-1101), following a determination by the FDA Data Safety Monitoring Board trials, that the UNITY-CLL trial data was not mature enough to continue. On this news, TG Therapeutics dropped 44% to close at $5.15 per share, thereby injuring investors.
If you purchased TG Therapeutics securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.